These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16154721)

  • 1. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.
    Catalone BJ; Miller SR; Ferguson ML; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
    Biomed Pharmacother; 2005 Sep; 59(8):430-7. PubMed ID: 16154721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure.
    Catalone BJ; Ferguson ML; Miller SR; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
    Biomed Pharmacother; 2005 Sep; 59(8):460-8. PubMed ID: 16154719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety evaluation of the candidate vaginal microbicide C31G.
    Catalone BJ; Kish-Catalone TM; Neely EB; Budgeon LR; Ferguson ML; Stiller C; Miller SR; Malamud D; Krebs FC; Howett MK; Wigdahl B
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1509-20. PubMed ID: 15793133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.
    Krebs FC; Miller SR; Malamud D; Howett MK; Wigdahl B
    Antiviral Res; 1999 Oct; 43(3):157-73. PubMed ID: 10551374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9.
    Thompson KA; Malamud D; Storey BT
    Contraception; 1996 May; 53(5):313-8. PubMed ID: 8724622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.
    Cummins JE; Doncel GF
    Sex Transm Dis; 2009 Mar; 36(3 Suppl):S84-91. PubMed ID: 19218890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures.
    Calis S; Yulug N; Sumnu M; Ayhan A; Hincal AA
    Boll Chim Farm; 1992 Oct; 131(9):335-8. PubMed ID: 1492969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical study of a C31G containing mouthrinse: effect on salivary microorganisms.
    Corner AM; Brightman VJ; Cooper S; Yankell SL; Malamud D
    J Clin Dent; 1990; 2(2):34-8. PubMed ID: 2090157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
    Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
    J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of suppository bases on the release properties of a potent antimicrobial agent (C31G).
    Caliş S; Sumnu M; Hincal AA
    Pharmazie; 1994 May; 49(5):336-9. PubMed ID: 8016179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.
    Mauck CK; Weiner DH; Creinin MD; Barnhart KT; Callahan MM; Bax R
    Contraception; 2004 Sep; 70(3):233-40. PubMed ID: 15325893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal toxicity studies of a gel formulation of native pokeweed antiviral protein.
    D'Cruz OJ; Waurzyniak B; Uckun FM
    Toxicol Pathol; 2004; 32(2):212-21. PubMed ID: 15200159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I comparative postcoital testing study of three concentrations of C31G.
    Mauck CK; Creinin MD; Barnhart KT; Ballagh SA; Archer DF; Callahan MM; Schmitz SW; Bax R
    Contraception; 2004 Sep; 70(3):227-31. PubMed ID: 15325892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide.
    D'Cruz OJ; Uckun FM
    Fertil Steril; 2004 Mar; 81 Suppl 1():831-41. PubMed ID: 15019817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice and rabbit models for oral and percutaneous absorption and disposition of amphoteric surfactant C31G.
    Michaels EB; Hahn EC; Kenyon AJ
    Am J Vet Res; 1983 Oct; 44(10):1977-83. PubMed ID: 6638657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes.
    Krebs FC; Miller SR; Catalone BJ; Welsh PA; Malamud D; Howett MK; Wigdahl B
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1954-60. PubMed ID: 10858360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro.
    Wyrick PB; Knight ST; Gerbig DG; Raulston JE; Davis CH; Paul TR; Malamud D
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1335-44. PubMed ID: 9174195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
    Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque.
    Patton DL; Sweeney YT; Balkus JE; Hillier SL
    Sex Transm Dis; 2006 Nov; 33(11):691-5. PubMed ID: 16641825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C31G, a new agent for oral use with potent antimicrobial and antiadherence properties.
    Corner AM; Dolan MM; Yankell SL; Malamud D
    Antimicrob Agents Chemother; 1988 Mar; 32(3):350-3. PubMed ID: 3364952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.